Expertise in
2
conditions

Rachida Lebtahi

Paris, FR 
Expertise in
2
conditions
Paris, FR 

Overview

Rachida Lebtahi practices practicing medicine in Paris, France.

Lebtahi is highly rated in 2 conditions, according to our data. Their clinical expertise encompasses Neuroendocrine Tumor, SAPHO Syndrome, Liver Cancer, Hepato-Pancreato-Biliary Surgery, and Pancreaticoduodenectomy.

They are actively involved in clinical research, co-authoring 41 peer reviewed articles and participating in 1 clinical trial.

Locations

Paris, 75018, France
Other Locations
Clichy-sous-bois, France

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

1 Clinical Trials

Prospective, Multicenter, Randomized, Controlled Study Evaluating SIR-Spheres Y-90 Resin Microspheres Preceding Cisplatin-gemcitabine (CIS-GEM) Chemotherapy Versus CIS-GEM Chemotherapy Alone as First-line Treatment of Patients With Unresectable Intrahepatic Cholangiocarcinoma
Prospective, Multicenter, Randomized, Controlled Study Evaluating SIR-Spheres Y-90 Resin Microspheres Preceding Cisplatin-gemcitabine (CIS-GEM) Chemotherapy Versus CIS-GEM Chemotherapy Alone as First-line Treatment of Patients With Unresectable Intrahepatic Cholangiocarcinoma
Enrollment Status: Terminated
Publish Date: May 09, 2025
Intervention Type: Device, Drug
Study Drug: Cisplatin-Gemcitabine
Study Phase: Phase 2/Phase 3

41 Total Publications

Comparison of pre-therapeutic [99mTc]Tc-MAA SPECT/CT and post-therapeutic 90Y-PET/CT dosimetry for outcome prediction in hepatocellular carcinoma treated with resin microspheres.
Comparison of pre-therapeutic [99mTc]Tc-MAA SPECT/CT and post-therapeutic 90Y-PET/CT dosimetry for outcome prediction in hepatocellular carcinoma treated with resin microspheres.
Journal: European journal of nuclear medicine and molecular imaging
Published: December 15, 2025

Frequently Asked Questions about Rachida Lebtahi

Is Rachida Lebtahi a top-rated expert for Neuroendocrine Tumor?

MediFind is an objective health platform that identifies experts based on real-world data. Rachida Lebtahi is classified as an Advanced expert for Neuroendocrine Tumor, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

Does Rachida Lebtahi participate in research or clinical trials?

Yes. Rachida Lebtahi has published 41 articles and abstracts on conditions like Neuroendocrine Tumor. You can view a list of Rachida Lebtahi's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Lebtahi's expertise for a condition
ConditionClose
      View All 17 Experienced Conditions
      Want to save this expert for later?
      Sign Up
      Not sure about your diagnosis?
      Check Your Symptoms
       
       
       
       
      Learn about our expert tiers
      Learn More
      Are you the provider on this profile?
      Claim Profile